Clinical Trial

Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

Study acronym: Find-AF2
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients who have suffered a stroke are having an increased risk of having recurrent stroke in the future. This risk of stroke is increased by atrial fibrillation, which often "comes and goes" (called paroxysmal) and hence escapes routine diagnostics. The hypothesis of Find-AF 2 is that enhanced (evaluation in a ECG core lab), prolonged (at least 7 days of rhythm monitoring annually) and intensified (continuous rhythm monitoring in high risk patients) not only finds atrial fibrillation more often, but that changes in therapeutic management (e. g. start of anticoagulation after detection of atrial fibrillation) results in a decrease of cardioembolism (which can be either recurrent stroke or systemic embolism). To prove this hypothesis, patients will be randomised into two groups: the first group will receive the currently available standard care for patients with stroke. In the second group, cardiac rhythm monitoring adapted to the risk of the occurrence of atrial fibrillation is performed - either with a 7-day long-term ECG (at baseline, after 3 and 12 months and every 12 months thereafter) or with continuous monitoring using an implantable cardiac monitor. If atrial fibrillation is detected, this information will be given to the treating study physician. Any therapeutic decision is at the discretion of the treating physician, but should follow current guidelines.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2020-04-30; most recent amendment 2025-05-29.
Status change: Recruiting → Active, Not Recruiting 2025-01-17
Status change: Not Yet Recruiting → Recruiting 2020-07-09
Trial Details
NCT Number NCT04371055
Lead Sponsor University of Leipzig
Collaborators: Johannes Gutenberg University Mainz
Conditions Ischemic Stroke, Atrial Fibrillation
Enrollment 5,227 participants
Start Date 2020-07-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04